Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | LGMN | Q99538 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27869427 | 0.88 | GSK3B (0.48) | GSK3BLGMNSIGMAR1ALDH1A1KDM4E | |
| SCHEMBL31618396 | 0.84 | LRRK2 (0.49) | GSK3BLGMNSIGMAR1ALDH1A1KDM4E | |
| SCHEMBL23647758 | 0.84 | LRRK2 (0.49) | GSK3BLGMNSIGMAR1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL28059785 | 0.83 | LGMN (0.44) | LGMNSIGMAR1ALDH1A1KDM4EALOX15 | |
| SCHEMBL1662572 | 0.81 | GSK3B (0.40) | GSK3BLGMNALDH1A1KDM4EALOX15 | |
| SCHEMBL23662641 | 0.80 | LGMN (0.42) | GSK3BLGMNSIGMAR1ALDH1A1KDM4E | |
| SCHEMBL20424580 | 0.79 | KMO (0.48) | GSK3BALDH1A1KDM4EALOX15HPGD | |
| SCHEMBL19280328 | 0.78 | MEN1 (0.49) | GSK3BLGMNALDH1A1KDM4EALOX15 | |
| SCHEMBL23647703 | 0.78 | PIK3CA (0.46) | GSK3BSIGMAR1ALDH1A1MAPTMEN1 | |
| SCHEMBL31618493 | 0.78 | PKM (0.46) | LGMNSIGMAR1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115066428-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021143924-A1 | BORIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| WO-2021143924-A1 | BORIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9040545-B2 | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors | CELLZOME LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | GSK3B 614/4885LGMN 4870/4885SIGMAR1 2341/4885 |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | JAK1, JAK3, JAK2 | GSK3B 585/4885LGMN 4873/4885SIGMAR1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.